![conference banner](/images/conference-banner.jpeg)
Abstract
The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Current Pharmaceutical Biotechnology
Title: Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009)
Volume: 10 Issue: 8
Author(s): Leyre Zuniga and Begona Calvo
Affiliation:
Abstract: The prime difference between generics and biosimilars is that while generics contain the exact active ingredient as in the originator product, biosimilars are only “similar” and not “identical” to the originator biological medicine. This difference appears due to the nature of the biopharmaceutical medicines which are extremely complex to manufacture (it is not possible to make an exact copy of a biotech medicine in the same way as a traditional chemical molecule can be copied). In fact, it is widely accepted that for biopharmaceuticals, the “process is the product”. Minor changes during the manufacturing process can have critical consequences in the patients. The vast majority of the biopharmaceuticals on the market are produced by genetic engineering using various recombinant expression systems. Most of the recombinant proteins that have been granted marketing approval to date are produced either in E. Coli or in recombinant mammalian cell lines. Several approaches may be undertaken to determine biopharmaceuticals potency. Bioassays represent the most relevant potency-determining assay, as they directly assess the biological activity of the product. These assays involve applying a known quantity of the substance to be analyzed to a biological system which responds to this applied stimulus. The response is measured quantitatively, allowing an activity value to be assigned to the substance being assayed.
Export Options
About this article
Cite this article as:
Zuniga Leyre and Calvo Begona, Global Vision about the Biological Medicinal Products: Biosimilars (April, 2009), Current Pharmaceutical Biotechnology 2009; 10 (8) . https://dx.doi.org/10.2174/138920109789978702
DOI https://dx.doi.org/10.2174/138920109789978702 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Transplantation of Pancreatic Islets Immobilized in Alginate-Based Microcapsules: From Animal Studies to Clinical Trials
Micro and Nanosystems Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topics Anxiety Disorders, Advances in Neurobiology and Neuropharmacology (Executive Guest Editor: Dirk Wedekind)]
Current Pharmaceutical Design An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes
Current Topics in Medicinal Chemistry Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry Biophysical Insight into Protein Folding, Aggregate Formation and its Inhibition Strategies
Protein & Peptide Letters Structurally Constrained Insulin Analogs by Directed Stepwise Crosslinking
Protein & Peptide Letters Structure-Based Design in the GPCR Target Space
Current Medicinal Chemistry Endocrine Disruptor Agent Nonyl Phenol Exerts An Estrogen-like Transcriptional Activity on Estrogen Receptor Positive Breast Cancer Cells
Current Medicinal Chemistry Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Perspectives on the Development of Antioxidant Antiepileptogenic Agents
Mini-Reviews in Medicinal Chemistry Biological Ageing, Inflammation and Nutrition: How Might They Impact on Systemic Sclerosis?
Current Aging Science Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design Localization Patterns of Sumoylation Enzymes E1, E2 and E3 in Ocular Cell Lines Predict Their Functional Importance
Current Molecular Medicine Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Early Urinary Markers for Diabetic and Other Kidney Diseases
Current Drug Targets Indoxyl Sulfate: A Candidate Target for the Prevention and Treatment of Cardiovascular Disease in Chronic Kidney Disease
Current Drug Targets Study of Cord Blood Erythropoietin, Leptin and Adiponectin Levels in Neonates with Hypoxic Ischemic Encephalopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Testicular Dysfunction is a Common Feature in Men with Type 2 Diabetes Mellitus in a Nigerian Tertiary Hospital
Current Diabetes Reviews